Group 1 - The company held its fifth board meeting on March 13, 2026, where all 9 attending directors approved several resolutions [2][4] - The board approved the repurchase and cancellation of 61,000 A-share restricted stocks from 5 departing incentive recipients as per the 2025 A-share restricted stock incentive plan [2][21] - The company plans to amend its articles of association to reflect changes in registered capital from 360,593,720 yuan to 360,780,970 yuan due to stock repurchase [6][7] Group 2 - The board approved the revision of the company's ESG management policy for suppliers to enhance sustainable development practices [9][10] - The company will use up to 450 million yuan of idle funds to purchase low-risk financial products to improve fund utilization efficiency [11][28] - The board authorized the management to make investment decisions within the approved limits for the financial products [31][32] Group 3 - The repurchase price for the restricted stocks is set at 36.42 yuan per share for the initial grant and 53.24 yuan per share for the reserved grant [21] - The total amount for the stock repurchase is 2,305,720 yuan, sourced from the company's own funds [22] - The repurchase will not materially affect the company's financial status or operational results, nor will it impact the ongoing stock incentive plan [23][24]
凯莱英医药集团(天津)股份有限公司 第五届董事会第七次会议决议的公告